| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10900512 | Cancer Letters | 2005 | 8 Pages |
Abstract
The efficacy of locoregional radioimmunotherapy (RIT) in treating peritoneal tumors of colon cancer of <2Â mm in diameter was examined at maximum tolerated doses, focusing the comparison between 186Re and 131I labeled to an anti-colorectal cancer IgG1. Estimated radiation doses to tumors were considerably higher with 186Re-RIT than with 131I-RIT. The advantage of 186Re-RIT decreased with decreasing tumor size, but 186Re-RIT delivered 1.6-times higher radiation to tumors of 1Â mm. Consequently, 186Re-RIT attained better survival of mice than 131I-RIT or chemotherapy with 5-fluorouracil did. Therefore, locoregional 186Re-RIT may be an option in an adjuvant setting of colon cancer with high risk of peritoneal dissemination.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Seigo Kinuya, Kunihiko Yokoyama, Mishiroku Izumo, Takami Sorita, Takashi Obata, Hirofumi Mori, Kazuhiro Shiba, Naoto Watanabe, Noriyuki Shuke, Takatoshi Michigishi, Norihisa Tonami,